Compare Novavax Inc (NVAX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Teradyne, Inc. — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Teradyne, Inc. trades at $372.62 (market cap $52.25B). The key difference: Teradyne, Inc. is far larger — about 40.2× Novavax Inc's market cap, and Teradyne, Inc. pays a 0.16% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TER | |
|---|---|---|
Market Cap | $1.30B | $52.25B |
Sector | Health | Technology |
52-Week High | $11.19 | $483.84 |
52-Week Low | $6.22 | $90.15 |
Enterprise Value | $800.50M | $52.08B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Teradyne (TER) trades at $374.15, up 16.07% in 24 hours, with strong quarterly earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but maintains solid fundamentals with 22.55% net income margin and 28.75% ROE. Recent institutional activity includes Amova Asset Management reducing its position by 49.5% in Q1 2026 while maintaining bullish analyst consensus.
TER presents compelling growth potential from AI infrastructure expansion but faces valuation concerns with a 61.92 P/E ratio. The upcoming Q2 2026 earnings report on July 28, 2026, will be crucial for validating the AI-driven growth narrative. Risks include competitive pressures and market volatility, though analyst consensus targets $459.60 suggest 23% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
